Aprea Therapeutics (APRE) Competitors $1.49 -0.02 (-1.32%) Closing price 10/15/2025 03:59 PM EasternExtended Trading$1.54 +0.05 (+3.36%) As of 10/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APRE vs. RANI, XFOR, TENX, SCYX, ANVS, XCUR, KZR, AKTX, TAOX, and RNTXShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Rani Therapeutics (RANI), X4 Pharmaceuticals (XFOR), Tenax Therapeutics (TENX), SCYNEXIS (SCYX), Annovis Bio (ANVS), Exicure (XCUR), Kezar Life Sciences (KZR), Akari Therapeutics (AKTX), Synaptogenix (TAOX), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. Its Competitors Rani Therapeutics X4 Pharmaceuticals Tenax Therapeutics SCYNEXIS Annovis Bio Exicure Kezar Life Sciences Akari Therapeutics Synaptogenix Rein Therapeutics Aprea Therapeutics (NASDAQ:APRE) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations. Does the media refer more to APRE or RANI? In the previous week, Aprea Therapeutics had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 4 mentions for Aprea Therapeutics and 2 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.95 beat Aprea Therapeutics' score of 0.32 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aprea Therapeutics Neutral Rani Therapeutics Positive Which has better earnings & valuation, APRE or RANI? Aprea Therapeutics has higher revenue and earnings than Rani Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAprea Therapeutics$1.50M5.79-$12.96M-$2.32-0.64Rani Therapeutics$1.03M34.22-$30.02M-$0.91-0.54 Which has more risk & volatility, APRE or RANI? Aprea Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Is APRE or RANI more profitable? Rani Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,645.01%. Aprea Therapeutics' return on equity of -78.90% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aprea Therapeutics-1,645.01% -78.90% -62.67% Rani Therapeutics N/A -1,258.76%-97.97% Do analysts recommend APRE or RANI? Aprea Therapeutics presently has a consensus price target of $15.50, indicating a potential upside of 940.27%. Rani Therapeutics has a consensus price target of $7.33, indicating a potential upside of 1,395.38%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Aprea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals believe in APRE or RANI? 34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 13.6% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 45.1% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryRani Therapeutics beats Aprea Therapeutics on 9 of the 16 factors compared between the two stocks. Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.80M$3.36B$6.11B$10.46BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-0.6422.7785.3627.36Price / Sales5.79469.27605.35135.57Price / CashN/A46.7037.4661.86Price / Book0.4210.5512.436.81Net Income-$12.96M-$52.58M$3.32B$276.80M7 Day Performance0.88%0.09%0.58%0.42%1 Month Performance2.41%15.61%10.53%7.86%1 Year Performance-57.43%15.13%72.99%41.24% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics2.4609 of 5 stars$1.49-1.3%$15.50+940.3%-51.6%$8.80M$1.50M-0.647News CoverageHigh Trading VolumeRANIRani Therapeutics3.3299 of 5 stars$0.48+1.6%$7.33+1,440.6%-76.9%$34.28M$1.03M-0.52110XFORX4 Pharmaceuticals4.2632 of 5 stars$3.00-2.0%$34.17+1,039.3%-82.9%$34.12M$2.56M-0.2080TENXTenax Therapeutics2.6349 of 5 stars$7.46+0.6%$18.00+141.4%+89.2%$34.00MN/A-8.109News CoverageAnalyst ForecastSCYXSCYNEXIS0.654 of 5 stars$0.80-1.2%N/A-46.4%$33.66M$3.75M-2.0160News CoverageAnalyst ForecastGap UpANVSAnnovis Bio2.898 of 5 stars$1.70+2.4%$17.33+919.6%-77.3%$33.13MN/A-0.833News CoverageGap UpXCURExicure1.7432 of 5 stars$5.08-1.2%N/A+126.2%$32.11M$500K-1.3150KZRKezar Life Sciences3.8334 of 5 stars$4.33+0.9%$9.00+107.9%-50.6%$31.70M$7M-0.4560AKTXAkari Therapeutics3.1428 of 5 stars$0.96+2.1%$3.30+243.0%-67.9%$31.38MN/A0.009News CoverageGap DownTAOXSynaptogenix0.1949 of 5 stars$8.98-5.9%N/AN/A$31.34MN/A-0.454Gap UpRNTXRein Therapeutics3.1413 of 5 stars$1.33+0.8%$10.00+651.9%N/A$31.00MN/A-0.499 Related Companies and Tools Related Companies RANI Competitors XFOR Competitors TENX Competitors SCYX Competitors ANVS Competitors XCUR Competitors KZR Competitors AKTX Competitors TAOX Competitors RNTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APRE) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
